<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04136587</url>
  </required_header>
  <id_info>
    <org_study_id>17-199 ex 05/06</org_study_id>
    <nct_id>NCT04136587</nct_id>
  </id_info>
  <brief_title>The Bacterial Secretome in IBD</brief_title>
  <official_title>The Bacterial Secretome in Crohn's Disease and Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Secreted bacterial effectors produced by the intestinal microbiota are in part responsible&#xD;
      for the proinflammatory effect of the fecal content in inflammatory bowel disease (IBD)&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fecal colonic content will be collected by suction during routine colonoscopy. From the fecal&#xD;
      content different fractions (containing soluble bacterial fractions and membrane bound&#xD;
      bacterial fractions) will be processed. These bacterial fractions (also termed as bacterial&#xD;
      secretome) will be tested for proinflammatory potential in tissue culture assays including&#xD;
      epithelial colonic cell lines and dendritic/monocytic cell lines. The main outcome parameter&#xD;
      will be the secretion of proinflammatory cytokines from the tissue culture.&#xD;
&#xD;
      For this purpose the investigators will test different groups of patients including patients&#xD;
      with active/inactive Crohn's disease or ulcerative colitis, patients with other inflammatory&#xD;
      conditions of the colon, patients with colorectal carcinoma and healthy controls undergoing&#xD;
      colonoscopy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of proinflammatory cytokines of bacterial fractions in IBD compared to healthy controls</measure>
    <time_frame>One day</time_frame>
    <description>Measurement of proinflammatory cytokines (f.e.: IL-8) in epithelial and dendritic tissue culture assays</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of proinflammatory cytokines of bacterial fractions in relation to disease activity</measure>
    <time_frame>One day</time_frame>
    <description>Measurement of proinflammatory cytokines (f.e.: IL-8) in epithelial and dendritic tissue culture assays</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of proinflammatory cytokines of bacterial fractions in relation to disease type</measure>
    <time_frame>one day</time_frame>
    <description>Measurement of proinflammatory cytokines (f.e.: IL-8) in epithelial and dendritic tissue culture assays</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of proinflammatory cytokines of bacterial fractions in other colonic diseases</measure>
    <time_frame>One day</time_frame>
    <description>Measurement of proinflammatory cytokines (f.e.: IL-8) in epithelial and dendritic tissue culture assays</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inclusion criteria:&#xD;
Colonoscopy performed for the following indications: anemia, blood in stool, constipation, change in bowel habits, screening for colon cancer, follow up after polyps, weight loss&#xD;
Macroscopic normal colonoscopy except for diverticulosis (without any signs of inflammation), ≤ 3 polyps (except hyperplastic polyps of the colon and rectum), angiodysplasia&#xD;
Exclusion criteria:&#xD;
Diagnosis of IBD or any other inflammatory condition of the small and large intestine&#xD;
Diagnosis of irritable bowel syndrome (IBS)&#xD;
Autoimmune disorders&#xD;
Obesity (BMI&gt; 30)&#xD;
Regular intake of NSAIDs (&gt; 2 tablets/ week), immunosuppressants&#xD;
Intake of antibiotics within the last 3 months&#xD;
Intestinal infection by enteric pathogens&#xD;
Probiotic therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crohn's disease</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 Subgroups: inactive disease (10 patients) and active disease (10 patients)&#xD;
Inclusion criteria:&#xD;
Colonoscopy indicated by routine clinical care&#xD;
Established diagnosis of Crohn´s disease (also if established by the study colonoscopy)&#xD;
Exclusion criteria:&#xD;
• Intestinal infection by enteric pathogens</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ulcerative Colitis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 Subgroups: inactive disease (10 patients) and active disease (10 patients)&#xD;
Inclusion criteria:&#xD;
Colonoscopy indicated by routine clinical care&#xD;
Established diagnosis of ulcerative colitis (also if established by the study colonoscopy)&#xD;
Exclusion criteria:&#xD;
• Intestinal infection by enteric pathogens</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colorectal carcinoma</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inclusion criteria:&#xD;
• Diagnosis of a lesion with suspicion for colorectal cancer during endoscopy which is confirmed later by histology&#xD;
Exclusion criteria:&#xD;
• None</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colitis/Enteritis of other origin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inclusion criteria:&#xD;
Diagnosis of intestinal inflammation at endoscopy or histology&#xD;
E.g.: Infectious colitis /enteritis; ischemic Colitis; microscopic colitis; graft versus host disease (GVHD); NSAID colitis; Colitis of unknown cause&#xD;
Exclusion criteria:&#xD;
• None</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Colonic fluid collection during endoscopy for analysis of the bacterial secretome</intervention_name>
    <description>Colonic content will be collected by suction during routine colonoscopy including the residual fluid in the colon and stool contents and also suction of washing fluid (sterile physiologic H2O solution)</description>
    <arm_group_label>Colitis/Enteritis of other origin</arm_group_label>
    <arm_group_label>Colorectal carcinoma</arm_group_label>
    <arm_group_label>Crohn's disease</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_label>Ulcerative Colitis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Group 1 (healthy controls): n=20&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Colonoscopy performed for the following indications: anemia, blood in stool,&#xD;
             constipation, change in bowel habits, screening for colon cancer, follow up after&#xD;
             polyps, weight loss&#xD;
&#xD;
          -  Macroscopic normal colonoscopy except for diverticulosis (without any signs of&#xD;
             inflammation), ≤ 3 polyps (except hyperplastic polyps of the colon and rectum),&#xD;
             angiodysplasia&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Diagnosis of IBD or any other inflammatory condition of the small and large intestine&#xD;
&#xD;
          -  Diagnosis of IBS&#xD;
&#xD;
          -  Autoimmune disorders&#xD;
&#xD;
          -  Obesity (BMI&gt; 30)&#xD;
&#xD;
          -  Regular intake of NSAIDs (&gt; 2 tablets/ week), immunosuppressants&#xD;
&#xD;
          -  Intake of antibiotics within the last 3 months&#xD;
&#xD;
          -  Intestinal infection by enteric pathogens&#xD;
&#xD;
          -  Probiotic therapy&#xD;
&#xD;
        Group 2 (Crohn´s disease; CD): n= 20 (10 active CD; 10 inactive CD)&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Colonoscopy indicated by routine clinical care&#xD;
&#xD;
          -  Established diagnosis of Crohn´s disease (also if established by the study&#xD;
             colonoscopy)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        • Intestinal infection by enteric pathogens&#xD;
&#xD;
        Definition of active CD Harvey-Bradshaw Index - HBI ≥ 5 and / or Simple Endoscopic Score&#xD;
        for Crohn Disease (SES-CD) ≥ 3&#xD;
&#xD;
        Except SES-CD scores resulting from isolated lesions only located at the ileocolonic&#xD;
        anastomosis consistent with a modified Rutgeerts score i2a (these patients are considered&#xD;
        as endoscopically non active)&#xD;
&#xD;
        Definition of inactive CD&#xD;
&#xD;
        Harvey-Bradshaw Index (HBI) &lt; 5 and Simple Endoscopic Score for Crohn Disease (SES-CD) &lt; 3&#xD;
&#xD;
        Except SES-CD scores resulting from isolated lesions only located at the ileocolonic&#xD;
        anastomosis consistent with a modified Rutgeerts score i2a (these patients are considered&#xD;
        as endoscopically non active)&#xD;
&#xD;
        Group 3 (Ulcerative colitis, UC): n= 20 (10 active UC; 10 inactive UC)&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Colonoscopy indicated by routine clinical care&#xD;
&#xD;
          -  Established diagnosis of ulcerative colitis (also if established by the study&#xD;
             colonoscopy)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        • Intestinal infection by enteric pathogens&#xD;
&#xD;
        Definition of active UC Total Mayo score ≥ 3 and Endoscopic Mayo subscore ≥ 2&#xD;
&#xD;
        Definition of inactive UC Total Mayo score &lt; 3 and Endoscopic Mayo subscore 0 or 1.&#xD;
&#xD;
        Group 4 (Colorectal cancer): n= 10&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
        • Diagnosis of a lesion with suspicion for colorectal cancer during endoscopy which is&#xD;
        confirmed later by histology&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        • None&#xD;
&#xD;
        Group 5 (Colitis/Enteritis of different origin): n= 20&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Diagnosis of intestinal inflammation at endoscopy or histology&#xD;
&#xD;
          -  E.g.: Infectious colitis /enteritis; ischemic Colitis; microscopic colitis; GVHD;&#xD;
             NSAID colitis; Colitis of unknown cause&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        • None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Hoegenauer, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christoph Hoegenauer, Prof</last_name>
    <phone>004331638581786</phone>
    <email>christoph.hoegenauer@medunigraz.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andreas Blesl, Dr</last_name>
    <phone>004331638580989</phone>
    <email>andreas.blesl@medunigraz.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 10, 2019</study_first_submitted>
  <study_first_submitted_qc>October 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2019</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

